Toxic absorption of pimecrolimus in a patient with severe acute graft-versus-host disease [2]

Bone Marrow Transplantation

Volumn 36, Issue 10, 2005, Pages 919-920

  Neuman, D L ^a   Farrar, J E ^b   Moresi, J M ^c   Vogelsang, G B ^c   Higman, M A ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; PIMECROLIMUS; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLERGIC DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOIMMUNE DISEASE; BONE MARROW BIOPSY; CASE REPORT; DEATH; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY DYSFUNCTION; LETTER; LYMPHOCYTE TRANSFUSION; MALE; MENTAL DISEASE; NONMYELOABLATIVE CONDITIONING; PLASMAPHERESIS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; SKIN DISEASE; WHOLE BODY RADIATION; X CHROMOSOME LINKED DISORDER;

ABSORPTION; ADMINISTRATION, TOPICAL; AUTOIMMUNE DISEASES; BONE MARROW TRANSPLANTATION; CHILD, PRESCHOOL; GRAFT VS HOST DISEASE; HUMANS; MALE; SKIN DISEASES; TACROLIMUS;

EID: 27844507194     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705146     Document Type: Letter

References (13)

1. Zeiser R, Marks R, Bertz H, Finke J. Immunopathogenesis of acute graft-versus-host disease: Implications for novel preventive and therapeutic strategies. Ann Hematol 2004; 83: 551-565.
2. Ferguson PJ, Blanton SH, Saulsbury FT et al. Manifestations and linkage analysis in X-linked autoimmunity-immunodeficiency syndrome. Am J Med Genet 2000; 90: 390-397.
3. Clark LB, Appleby MW, Brunkow ME et al. Cellular and molecular characterization of the scurfy mouse mutant. J Immunol 1999; 162: 2546-2554.
4. Sullivan KM, Deeg HJ, Sanders J et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 1986; 67: 1172-1175.
5. Shuster S. High-output cardiac failure from skin disease. Lancet 1963; 1: 1338-1340.
6. Russell RK, Richardson N, Wilson DC. Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. J Pediatr Gastroenterol Nutr 2001; 32: 207-208.
7. Ghislain PD, De Decker I, Lachapelle JM. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. Br J Dermatol 2004; 150: 1052-1053.
8. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Arch Dermatol 2002; 138: 1259-1260.
9. Kawashima M, Nakagawa H, Ohtsuki M et al. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet 1996; 348: 1240-1241.
10. Allen A, Siegfried E, Silverman R et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137: 747-750.
11. Kalia YN, Merino V, Guy RH. Transdermal drug delivery. Clinical aspects. Dermatol Clin 1998; 16: 289-299.
12. Spray A, Siegfried E. Dermatologic toxicology in children. Pediatr Ann 2001; 30: 197-202.
13. Ruzicka T, Assmann T, Homey B. Tacrolimus: The drug for the turn of the millennium? Arch Dermatol 1999; 135: 574-580.